LOGIN  |  REGISTER
Chimerix

Kovo+ Announces Management Appointments and Strategic Restructuring

December 11, 2024 | Last Trade: C$0.06 0.00 0.00

Vancouver, British Columbia--(Newsfile Corp. - December 11, 2024) - Kovo+ Holdings Inc. (TSXV: KOVO) (formerly Kovo HealthTech Corporation) ("Kovo" or the "Company") is pleased to announce the following organizational changes: Mr. Justin Anderson, formerly the Chief Restructuring Officer of the Company, has been appointed Chief Executive Officer. Mr. Brenner Adams, formerly the Interim Chief Executive Officer of the Company, has been appointed to the newly created position of Chief Strategy Officer. Mr. Mark Detz, formerly the Interim Chief Financial Officer of the Company, has been promoted to Chief Financial Officer.

"These changes reflect our commitment to strengthening leadership in an ever-evolving market and help drive the next phase of our business," said Peter Bak, Kovo Board Chair.

Kovo is also pleased to announce details of its strategic restructuring that refocuses the organization on artificial intelligence ("AI") initiatives to drive impact and innovation across diverse industries.  The Company's subsidiaries have been reorganized into two core, collaborative business segments: Medical Billing Services ("MBS") and AI Services.

"At Kovo, we believe that the future lies in innovation, and our strategic restructuring represents a bold step toward embracing the transformative potential of artificial intelligence. By focusing on AI-driven solutions and enhancing our operational capabilities, we are positioning ourselves in healthcare technology and committing our operations for a new era," said Justin Anderson, Chief Executive Officer of the Company.

HEAL Vue, Inc. dba Kovo RCM ("Kovo RCM"), an indirect wholly owned subsidiary of Kovo, has been established to manage the Company's MBS business segment. Kovo RCM is responsible for overseeing Kovo's acquisitions in the medical billing and revenue cycle management ("RCM") space and with a focus on the small and medium-sized business sector. Kovo RCM is structured to integrate Kovo's RCM assets and brands into a unified service platform is expected to provide comprehensive RCM solutions to clinics, practices, providers, and rural hospitals, to optimize their revenue cycles and operational efficiency. Nick Jose has been appointed as the President and Chief Operating Officer of Kovo RCM. With his leadership, Kovo RCM is dedicated to offering innovative billing solutions and exceptional service tailored to the needs of healthcare providers in various specialties.

"Through Kovo RCM, we offer innovative billing and administrative services, as well as advanced AI, business process outsourcing, accelerated payments, practice management, and electronic health record platform solutions," said Brenner Adams, Chief Strategy Officer of the Company. "With the acquisition of the exclusive AccelVue AI healthcare license from HEAL USA, Inc., Kovo is taking a strategic step towards integrating cutting-edge AI technologies into our services."

Kovo also plans to leverage our exclusive AI platform technology relationship to exploit AI services and solution opportunities in the broader healthcare strategy. Kovo aims to make this a key pillar of its long-term plan, positioning it as a growing and significant vertical within the Kovo portfolio. This move reflects our commitment to providing innovative solutions that enhance operational efficiency and support the growing needs of the healthcare industry.

About Kovo+ Holdings Inc.

Kovo is a versatile technology company leading the charge in AI initiatives to drive impact and innovation across diverse industries. Kovo remains committed to its core business-model of strategic growth opportunities within mid-market Medical Billing firms, where exploitive business optimization synergies exist. Moving forward, Kovo will integrate accretive broader healthcare sector additions to its portfolio and opportunities beyond in multiple new markets. Dedicated to revolutionizing business processes optimization through technological advancements and evolving AI applied methods, Kovo embodies a commitment to ensured and enduring profitability. To learn more about Kovo and to keep up to date on Kovo news, visit www.kovoplus.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking information. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as "anticipate", "proposed", "estimates", "would", "expects", "intends", "plans", "may", "will", and similar expressions. Forward-looking statements or information are based on a number of factors and assumptions that have been used to develop such statements and information, but which may prove to be incorrect. Although the Company believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this press release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement.

Contact Information

For further information, please contact:

Peter Bak, Board Chair
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-866-558-6777

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

Astria Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB